Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2213PDF: 1740HTML: 386 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2951PDF: 1389HTML: 3583Untitled: 203Untitled: 216Untitled: 191 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
829PDF: 107HTML: 149 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
527PDF: 260HTML: 104 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1088PDF: 1196Suppl. Files: 575HTML: 94 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1286PDF: 1087HTML: 220 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1427HTML: 486PDF: 846 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3860PDF: 1699HTML: 11659Figures Haase: 220 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3401PDF: 1998HTML: 7484 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
2032PDF: 744HTML: 690Table1: patient's characteristics: 162Table 2: profile of each patient: 186 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2510HTML: 287PDF: 919 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3603PDF: 1250HTML: 5008Incidence age-standardized rates for HL across the Mediterranean basin: 219 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3312PDF: 1731HTML: 1103 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2630PDF: 819HTML: 5241 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9215PDF: 6139HTML: 87998Fig.1b: 197Fig.1c: 205Fig.2a: 191Fig.2b: 190Fig.4: 207Fig.2c: 194Fig.3: 195Tab.1: 246Tab.2: 220Tab.3: 205Tab.4: 240Fig1a: 203 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1610PDF: 1059HTML: 263 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3632PDF: 2553HTML: 1525 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3716PDF: 913HTML: 6729 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2649PDF: 1031HTML: 180Suppl. Files: 525 -
SOLITARY PLASMACYTOMA
3983PDF: 2227HTML: 1253fIGURES 1,2: 235 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3690PDF: 1693HTML: 2685 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2224PDF: 1636HTML: 323 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3114PDF: 890HTML: 7179Kost Fig1: 200Kost Fig 2: 191Kost Fig3: 193Kost Fig 4: 203Kost Fig5: 202Kost fig 6: 188 -
-
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4064PDF: 1562HTML: 9194Untitled: 287Untitled: 194Untitled: 180Untitled: 172Untitled: 196Untitled: 352 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2518PDF: 802HTML: 1742 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2824PDF: 1149HTML: 3299 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4033PDF: 1071HTML: 3608Untitled: 180Cneo. Fig.1: 117Untitled: 109Untitled: 137Untitled: 137 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2867PDF: 1034HTML: 5531 -







